secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K/A
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0001193125-25-129849
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha reports FDA-aligned pivotal trial for TSHA-102; 100% of Part A patients gained milestones
--------------------------------------------------------------------------------

- FDA aligned on single-arm pivotal Part B trial (N=15) for TSHA-102 in Rett syndrome patients ≥6 years; primary endpoint: developmental milestone gain/regain.
- Part A: 100% (10/10) of patients aged 6-21 gained ≥1 milestone; high dose showed faster and deeper effects vs low dose.
- Natural history data (~1,100 patients) showed ~0% likelihood of milestone gain/regain after age 6, supporting trial design.
- No treatment-related SAEs or DLTs; all related AEs mild-to-moderate across 12 patients.
- Company suspended $100M ATM prospectus; Sales Agreement remains in effect; new prospectus required for future sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525129849/0001193125-25-129849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312525129849/d907074d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-129849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer